NCT04380701 - A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults | Biotech Hunter

Enrollment

512

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

April 13, 2022

Conditions

Infections, RespiratoryVirus DiseasesInfection ViralVaccine Adverse ReactionRNA Virus InfectionsProtection Against COVID-19 and Infections With SARS CoV 2

Interventions

BIOLOGICAL

BNT162a1

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

BIOLOGICAL

BNT162b1

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

BIOLOGICAL

BNT162b2

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

BIOLOGICAL

BNT162c2

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Trial Locations (5)

Unknown

Contract Research Organization, Berlin

Universitäts Klinikum, Frankfurt am Main

Universitäts Klinikum, Heidelberg

Contract Research Organization, Kiel

Contract Research Organization, Mannheim